Mail

ENTA - Enanta Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

90.16

-0.78 (-0.86%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	90.94
Open	90.89
Bid	0.00 x 800
Ask	0.00 x 800
Day's Range	89.67 - 92.38
52 Week Range	64.08 - 127.77
Volume	106,446
Avg. Volume	191,384

Market Cap	1.773B
Beta (3Y Monthly)	1.41
PE Ratio (TTM)	24.35
EPS (TTM)	3.70
Earnings Date	Aug 6, 2019
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	108.43

Trade prices are not sourced from all markets

All

News

Press Releases

Benzinga6 days ago
Enanta's Respiratory Virus Drug Aces Midstage Study
The thinly traded, small-cap biotech Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) announced results Friday from a midstage study. What Happened Enanta released top-line results from a Phase 2a study that ...
Simply Wall St.6 days ago
How Much Did Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Pocket Last Year?
Jay Luly became the CEO of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in 2003. This analysis aims first to contrast...
Reuters6 days ago
UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial
Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study. The therapy, EDP-938, developed for treating respiratory syncytial virus (RSV) infection which currently has no available treatment, also helped improve symptoms in patients compared to placebo, the company said. RSV could lead to serious lung infections and even death in babies and the elderly who have a weaker immune system.
Business Wire6 days ago
Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results that demonstrated that EDP-938 achieved highly statistically significant (p
Business Wire10 days ago
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
CNW Group10 days ago
AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
CNW Group21 days ago
AbbVie's MAVIRET™ now listed in New Brunswick
AbbVie's MAVIRET™ now listed in New Brunswick
Thomson Reuters StreetEventslast month
Edited Transcript of ENTA earnings conference call or presentation 7-May-19 8:30pm GMT
Q2 2019 Enanta Pharmaceuticals Inc Earnings Call
Simply Wall St.last month
Do Enanta Pharmaceuticals's (NASDAQ:ENTA) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Business Wirelast month
Enanta Pharmaceuticals to Present at Upcoming Investor Conference
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
Motley Foollast month
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript
ENTA earnings call for the period ending March 31, 2019.
Zackslast month
Enanta Pharmaceuticals (ENTA) Beats Q2 Earnings Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 322.22% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Associated Presslast month
Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Watertown, Massachusetts-based company said it had net income of 20 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
Business Wirelast month
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019
Webcast and Conference Call today at 4:30 p.m. ET
Insider Monkey2 months ago
Here’s What Hedge Funds Think About Enanta Pharmaceuticals Inc (ENTA)
Is Enanta Pharmaceuticals Inc (NASDAQ:ENTA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
Zacks2 months ago
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business Wire2 months ago
Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2019 after the U.S. markets close on May 7, 2019. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. Enanta will host a conference call and webcast on May 7 at 4:30 p.m. ET.
Market Realist2 months ago
VKTX or ENTA: What to Expect from Revenue Growth in 2019
What Are Analysts Recommending for VKTX and ENTA?(Continued from Prior Part)Growth drivers In November 2018, Viking Therapeutics (VKTX) issued a press release announcing positive results from its Phase 2 trial evaluating the efficacy of the 1-mg dose
Market Realist2 months ago
What Are Analysts Recommending for VKTX and ENTA?
What Are Analysts Recommending for VKTX and ENTA?Stock price movementOn April 12, Viking Therapeutics (VKTX) closed at $9.35, 6.22% lower than its previous closing price, 153.39% higher than its 52-week low of $3.69, and 61.04% below its 52-week
Business Wire2 months ago
Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress™ 2019
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that new preclinical data from Enanta’s wholly-owned development programs for hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH) will be presented at The International Liver Congress™ (ILC) 2019, in Vienna, Austria. New data include a presentation on development candidate EDP-514, Enanta’s core inhibitor for HBV that is expected to enter into a Phase 1 clinical study in the second half of 2019.
CNW Group2 months ago
AbbVie's MAVIRET™ now reimbursed in Quebec
AbbVie's MAVIRET™ now reimbursed in Quebec
Simply Wall St.2 months ago
Can You Imagine How Chuffed Enanta Pharmaceuticals's (NASDAQ:ENTA) Shareholders Feel About Its 216% Share Price Gain?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a com...
CNW Group3 months ago
AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™
AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™
Zacks3 months ago
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
Business Wire3 months ago
Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2019
Enanta Announces Data Presentations at the International Liver Congress 2019